Figure 2A depicts representative PAK1 staining in the TMA specimens. The results of the Wilcoxon rank-sum test showed significantly higher mean PAK1 immunostaining scores for LUSC specimens than for LUAD and bronchioloalveolar carcinoma specimens (1.03 vs. 0.57; Figure 2B). Table 1 summarizes the correlation between PAK1 expression and the clinical characteristics of patients with NSCLC. This evidence concerns the gene PAK1 and non-small cell lung carcinoma.